-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: October 2009
Panelists ponder when the window will open
Panelists in this afternoon’s business roundtable “Window Shopping – The Buyer’s Perspective on Today’s IPO Candidates” contemplated what it’s going to take to return to a vibrant IPO market. “What we need is public market examples of IPOs that are successful,” said Ashley Dombkowski, PhD, a managing director at MPM Capital. Daniel Lyons, PhD, CFA, an equity research analyst at Janus Capital added that having a lack of opportunities can make a company stand out Read More >
Healthcare reform: sustaining biotech innovation in a new world
The Eighth Annual BIO Investor Forum kicked off today with a plenary session on health care reform with expert panelists who are entrenched in the day-to-day debate of the most comprehensive changes ever proposed for the U.S. health care system. Panelists agreed that it’s been a long and complicated debate and the end of year deadline is ambitious yet within the realm of possibility. Michelle Easton, a partner at Tarplin, Downs and Young, LLC, asserted that Read More >
Guest blogger post: The Lure of Translational Research
As a breast cancer advocate, I am seduced by the lure of translational research and the promises of personalized medicine that will make the one size fits all approach to cancer treatment obsolete and possibly reduce over-treatment, toxicity, and treatment errors. I will be attending the BIO Technology Transfer Symposium and BIO Investor Forum next week and will look forward to hearing insights from biotech industry leaders. The Tech Transfer Symposium will address opportunities and Read More >
Encouraging Louisiana to Partner with BIO
Louisiana is one of just a few states that do not yet have a BIO affiliate. I was invited to speak to community leaders in New Orleans by Jim McNamara, a local real estate investor who is presently the Secretary of the Board of the New Orleans BioInnovation Center, a Member of the Greater New Orleans Biosciences Economic Development District and a Commissioner of the Downtown Development District of New Orleans. Jim believes biotechnology can Read More >
The Burrill Report Interview with Jim Greenwood
The Burrill Report’s Daniel Levine spoke with Jim Greenwood, president and CEO of BIO, about the upcoming Eighth Annual BIO Investor Forum’s opening plenary session on healthcare reform. Greenwood will be moderating the session, “Healthcare Reform: Sustaining Biotech Innovation in a New World.” Listen to the podcast.
